Clinical research on dendritic cell vaccines to prevent postoperative recurrence and metastasis of liver cancer

Genetics and Molecular Research

Volumn 14, Issue 4, 2015, Pages 16222-16232

  Sun, T Y ^a   Yan, W ^a   Yang, C M ^a   Zhang, L F ^a   Tang, H L ^a   Chen, Y ^a   Hu, H X ^a   Wei, X ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

Chemical treatment; Dendritic cells; Immune treatment; Liver; Metastasis; Recurrence

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 4; BIOLOGICAL MARKER; CANCER VACCINE; CYTOKINE; MEMBRANE ANTIGEN;

ADULT; ANAPHYLAXIS; ARTHRITIS; ARTICLE; ASTHMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RECURRENCE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOLYSIS; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOPROPHYLAXIS; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SKIN DISCOLORATION; SURVIVAL RATE; VOMITING; BLOOD; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELL; FOLLOW UP; IMMUNOLOGY; IMMUNOPHENOTYPING; LIVER NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIGENS, SURFACE; BIOMARKERS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; CYTOKINES; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84979901336     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.December.8.12     Document Type: Article

References (16)

1. Airoldi ID, Carlo E, Cocco C, Caci E, et al. (2009). IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One 4: e6119.
2. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, et al. (2001). Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61: 6451-6458.
3. Chau GY, Wu CW, Lui WY, Chang TJ, et al. (2000). Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann. Surg. 231: 552-558.
4. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, et al. (2000). Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 60: 354 2-3549.
5. Lee WC, Wang HC, Huang PF, Lia CR, et al. (2005). Vaccination of advanced hepatocellular carcinoma patients with tumor 1ysate-pulsed dendritic cells. J. Immunother 28: 496-506.
6. Mailliard RB, Dallal RM, Son YI and Lotze MT (2000). Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen. Immunol. Invest. 29:177-l85.
7. Mortara L, Giuliani L, De Lerma Barbaro A, Accolla RS, et al. (2007). Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer. Surg Oncol 16: S33-S36.
8. Parasole R, Izzo F, Perrone F, Pignata S, et al. (2001). Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin. Cancer Res. 7: 3504-3509.
9. Perambakam S, Hallmeyer S, Reddy S, Mahmud N, et al. (2006). Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol. Immunother 55: 1033.
10. Ruggieri A, Barbati C, and Momi W (2010). Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int. J. Cancer 127: 499.
11. Sun TY, Ye Wei, Liu QD, et al. (2010a). The preliminary study of the inducing culture of dendritic cells and the killing effect of the gastric cancer cell lines MKN45. J. Int. Onc. 37: 468-473.
12. Sun TY, Yan W, Liu QD, Zhou NX, et al. (2010b). The research on the killing effect of the dendritic cells in human peripheral blood stimulated by the CpG ODN1826 on gastric cancer cell. Chin. J. Clin. Phys. 4: 13-17.
13. Takayama T, Sekine T, Makuuchi M, Yamasaki S, et al. (2000). Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 356: 802-807.
14. Wigginton JM, Gruys E, Geiselhart L, Subleski J, et al. (2001). TFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108: 51-62.
15. Yamanaka R, Honma J, Tsuchiyayan, Yajima N, et al. (2005). Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor specific CD8+cytotoxic T cells in patients with malignant glioma. J. Nero Oncol. 72: 107-113.
16. Zhang LJ and Wang XZ (2006). Interleukin-10 and chronic liver disease. World J. Gast. 12: 1681-1685.